Thus, patients whose tumors expressed high levels of TALDO1 experienced a higher risk of recurrence and death from breast cancer (P < 0.05; Fig. 4c, d) compared to patients with tumors in the TALDO1 low group who had a more favorable clinical outcome. This evidence concerns the gene TALDO1 and breast carcinoma.